igg2c fitc antibody (SouthernBiotech)
Structured Review
![( A and B ) Serum anti-VLP antibody titers in control and BCAP KO mice immunized with 2 μg of VLPs containing ssRNA measured at 7, 14, 21, 28, and 35 days after immunization. ( C ) Fluorescence-activated cell sorting (FACS) plots of VLP-immunized control and BCAP KO mice splenocytes stained with fluorescent VLPs, showing VLP + cells in the B220 + gate. FSC-W, forward scatter width. ( D ) Proportion and count of spleen VLP + B cells [gated as in (C)] from control and KO mice immunized with 2 μg of VLPs for 35 days. ( E ) B220 + VLP + GC B cells were identified as Fas + CD38 − cells in control and KO mice. ( F ) Proportion and count of spleen VLP-specific GC B cells [gated as in (E)] from control and KO mice. ( G to I ) Splenocytes were gated as B220 + VLP + Fas − CD38 + non-GC B cells, and the frequencies and count of switched memory and IgM memory B cells were determined on the basis of IgM and IgD levels. ( J ) VLP-specific plasma cells of IgG or <t>IgG2c</t> isotype enumerated by ELISpot assay on bone marrow (BM) cells from control or KO mice harvested at day 35 after immunization. All data are from one of the two independent experiments yielding similar conclusions. Points represent individual mice ( n = 7 mice per group) with mean [(A) and (B)] or mean with SEM [(D) to (J)] shown. P values of less than 0.05 are shown: * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001, calculated with two-way analysis of variance (ANOVA) with multiple comparisons test [(A) and (B)] or Mann-Whitney U test [(D) to (J)]. A.U., arbitrary units.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_6990/pmc11566990/pmc11566990__sciadv.adp1747-f1.jpg)
Igg2c Fitc Antibody, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/igg2c fitc antibody/product/SouthernBiotech
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "B cell adapter for PI 3-kinase (BCAP) coordinates antigen internalization and trafficking through the B cell receptor"
Article Title: B cell adapter for PI 3-kinase (BCAP) coordinates antigen internalization and trafficking through the B cell receptor
Journal: Science Advances
doi: 10.1126/sciadv.adp1747
Figure Legend Snippet: ( A and B ) Serum anti-VLP antibody titers in control and BCAP KO mice immunized with 2 μg of VLPs containing ssRNA measured at 7, 14, 21, 28, and 35 days after immunization. ( C ) Fluorescence-activated cell sorting (FACS) plots of VLP-immunized control and BCAP KO mice splenocytes stained with fluorescent VLPs, showing VLP + cells in the B220 + gate. FSC-W, forward scatter width. ( D ) Proportion and count of spleen VLP + B cells [gated as in (C)] from control and KO mice immunized with 2 μg of VLPs for 35 days. ( E ) B220 + VLP + GC B cells were identified as Fas + CD38 − cells in control and KO mice. ( F ) Proportion and count of spleen VLP-specific GC B cells [gated as in (E)] from control and KO mice. ( G to I ) Splenocytes were gated as B220 + VLP + Fas − CD38 + non-GC B cells, and the frequencies and count of switched memory and IgM memory B cells were determined on the basis of IgM and IgD levels. ( J ) VLP-specific plasma cells of IgG or IgG2c isotype enumerated by ELISpot assay on bone marrow (BM) cells from control or KO mice harvested at day 35 after immunization. All data are from one of the two independent experiments yielding similar conclusions. Points represent individual mice ( n = 7 mice per group) with mean [(A) and (B)] or mean with SEM [(D) to (J)] shown. P values of less than 0.05 are shown: * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001, calculated with two-way analysis of variance (ANOVA) with multiple comparisons test [(A) and (B)] or Mann-Whitney U test [(D) to (J)]. A.U., arbitrary units.
Techniques Used: Control, Fluorescence, FACS, Staining, Clinical Proteomics, Enzyme-linked Immunospot, MANN-WHITNEY
